Clinical trials: Carcinoma of the Rectum
Colorectal Cancer
Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00016198
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 74 sites in United States
- Sponsor
- Prologue Research International
Colorectal Neoplasms, Adenocarcinoma of the Colon
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX…
- Conditions
- Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT02425683
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- US Oncology Research
Metastatic Colorectal Cancer, Colon Cancer
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- COMPANION-003 (NCT05513742)
- Testing
- CTX-009
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Compass Therapeutics
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Head and Neck Cancer, Lung Cancer
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
This pilot phase II study is designed as a test and retest study to investigate [F 18]HX4 as a reliable non-invasive PET imaging marker for detection of tumor hypoxia regions and to establish a threshold for [F 18]HX4 uptake in…
- Conditions
- Head and Neck Cancer, Lung Cancer, Liver Cancer, Rectal Cancer
- Trial name
- HX4-200 (NCT01075399)
- Testing
- [F 18]HX4
- Volunteers
- 50 people
- Sponsor
- Siemens Molecular Imaging
Rectal Cancer, Lung Cancer
A Phase I Clinical Trial of Bevacizumab Injection
Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd Biological similar drugs.
- Conditions
- Rectal Cancer, Lung Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- NCT05476341
- Testing
- Bevacizumab injection, Bevacizumab injection（Avastin）
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05983133
- Testing
- PF-08046052
- Where
- 24 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Colon Cancer, Breast Cancer
A Digimed Oncology PharmacoTherapy Registry
DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch (patch), and a mobile app, which records time-stamped medication type and dose alongside biometric activity.
- Conditions
- Colon Cancer, Breast Cancer, Rectal Cancer
- Trial name
- ADOPTR (NCT04088955)
- Testing
- DigiMeds
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Proteus Digital Health, Inc.
Pancreatic Cancer, Colorectal Cancer
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer
- Trial name
- NCT02574663
- Testing
- TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.